Notes from UCLA David Geffen School of Medicine ro

Notes from UCLA David Geffen School of Medicine roundtable

Otto Yang - cell immunology and HIV talk about clinical trials regarding CV.

Views CV as three stages.
1. Infection (antiviral prevention)>
2. early phase virus induced (remdesivir) >
3. later phase hyperinflammatory (IL-6R blockers and Leronlimab)

interruptors are in parenthesis.

Huge team effort never run a clinical trial - Active clinical trials
summary of three Trials

Remdesivir. failed in ebola trial administered via IV. perhaps effective in earlier disease or as prophylaxis. Trial will continue. with remdesivir + baricitinib.
selinexor FDA approved.
exportin-1 inihibitor orally delivered Side Effects nausea & cytopenias - 1/5th of FDA dose . could reduce both viral replication and immune activation. theoritically could have viral and immunological effects. very promising, and very early

LeronLimab Trial CU - exciting used as compassionate. blocks ccr5. reduce inflammatory cell trafficking to lungs /end organs. Early anecdotal evidence for COVID 19 800 patients in HIV. extremely safe.

Leron first 5 patients UCLA. mild to moderate.

1. C-reactive proteins drop signifcantly by day 4.

2. total lymphocyte counts are down and after Lero was injected the Blood Lymphocytes rose (Good)

mentioned Pre-print RANTES disruption as well.

CYDY continuing to provide cell samples to UCLA. was mentioned

Still on the call its in Q&A right now.